Revolutionary Cancer Vaccine Trials Inspired By Covid Jab Begin

The same tactics were utilized by the team behind the Oxford-AstraZeneca Covid vaccine, which potentially ‘revolutionize’ cancer treatment.

Revolutionary Cancer Vaccine Trials Inspired By Covid Jab Begin

According to the BBC, researchers have developed a two-dose cancer vaccination that uses the same viral vector technology as the Oxford Covid vaccine to boost anti-tumour T cells and decrease tumors in mice.

Revolutionary Cancer Vaccine Trials Inspired By Covid Jab Begin

The vaccine is designed to target MAGE proteins, which are located on the surface of many malignancies.

Professor Benoit Van den Eynde’s group at the University of Oxford’s Ludwig Institute for Cancer Research, together with co-author Professor Adrian Hill.

“The potential for this new vaccine platform to improve cancer treatment is huge,” says Adrian Hill, University of Oxford’s Lakshmi Mittal & Family Professorship of Vaccinology and Director of the Jenner Institute.

We can continue to address the major challenge of spreading the favorable impact of immunotherapy to benefit more patients by bringing these teams together.”

As part of a collaboration between Vaccitech Oncology Limited (VOLT) and Cancer Research UK’s Centre for Drug Development, the team plans to start its first human clinical trial.

Jenner Institute scientists licensed this vaccine technique, which uses various prime and boosts viral vectors, to Vaccitech Ltd, which was created in 2016. A novel therapeutic cancer vaccine, a strategic collaboration between the Ludwig Institute for Cancer Research and Vaccitech Plc.

Prof Adrian Hill, Director of the Jenner Institute at the University of Oxford, said, “Our cancer vaccines elicit significant CD8+ T cell responses that infiltrate tumors and show great potential in boosting the efficacy of immune checkpoint blockade therapy and improving outcomes for cancer patients.”

As part of a collaboration between Vaccitech Oncology Limited (VOLT) and Cancer Research UK’s Centre for Drug Development, the team plans to start its first human clinical trial.

As a result, when a cancer cell breaks a DNA strand, it is less likely to repair it properly. Depending on where the break occurs, the cell may die immediately or proliferate more slowly.

Radiation therapy employs a focused beam that is directed just at the tumor-bearing area of the body, with the dose precisely calculated to produce the least amount of collateral harm to healthy cells. Even so, radiation therapy increases your odds of getting second cancer by a little amount.

To enhance the levels of anti-tumour T cells and decrease tumors in mice, the researchers developed a two-dose cancer vaccination using the same viral vector technology employed in the Oxford COVID vaccine. The vaccine is designed to target MAGE proteins, which are located on the surface of many malignancies.

That cell can turn malignant if the break disrupts one of your DNA’s many tumor-suppressing genes. Cancer cells, on the other hand, are more sensitive to radiation than normal cells. Their ability to divide rapidly is one of the characteristics that distinguishes cancer cells, and this usually signifies that some of the DNA’s spellcheck mechanisms have been disabled.

As a result, when a cancer cell breaks a DNA strand, it is less likely to repair it properly. Depending on where the break occurs, the cell may die immediately or proliferate more slowly.

When used in conjunction with other anti-PD-1 immunotherapy treatments, the vaccine resulted in a larger reduction in tumor size and enhanced mouse survival.

Anti-PD-1 immunotherapy is a promising cancer treatment that works by stimulating anti-tumor T cells to attack cancer cells by removing the brakes on them. However, due to the low amounts of T cells found in the majority of cancer patients, it has thus far proven to be mainly useless.

This is where the Oxford-AstraZeneca vaccine’s technology comes in: a two-dose treatment can help increase the number of cancer-fighting CD8+ T cells.

Leave a Comment